Eiger Biopharmaceuticals Stock Today
| EIGR Stock | USD 2.05 0.44 27.33% |
Performance0 of 100
| Odds Of DistressOver 83
|
Eiger Biopharmaceutica is selling at 2.05 as of the 19th of April 2024; that is 27.33 percent increase since the beginning of the trading day. The stock's lowest day price was 1.61. Eiger Biopharmaceutica has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Eiger Biopharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 20th of January 2024 and ending today, the 19th of April 2024. Click here to learn more.
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Eiger BioPharmaceuticals, Inc. The company has 1.48 M outstanding shares of which 29.81 K shares are currently shorted by private and institutional investors with about 3.72 trading days to cover. More on Eiger Biopharmaceuticals
Moving together with Eiger Stock
| 0.7 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
| 0.62 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
Follow Valuation Odds of Bankruptcy
Financial Report 9th of May 2024
Eiger Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eiger Biopharmaceutica's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eiger Biopharmaceutica or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO Director | MBA MD |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Eiger Biopharmaceuticals (EIGR) is traded on NASDAQ Exchange in USA and employs 56 people. Eiger Biopharmaceutica is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.55 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eiger Biopharmaceutica's market, we take the total number of its shares issued and multiply it by Eiger Biopharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eiger Biopharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 1.48 M outstanding shares of which 29.81 K shares are currently shorted by private and institutional investors with about 3.72 trading days to cover.
Eiger Biopharmaceuticals currently holds about 141.79 M in cash with (74.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Eiger Biopharmaceutica Probability Of Bankruptcy
Ownership Allocation30% of Eiger Biopharmaceuticals outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change.
Check Eiger Ownership Details
Eiger Stock Price Odds Analysis
In regard to a normal probability distribution, the odds of Eiger Biopharmaceutica jumping above the current price in 90 days from now is about 97.0%. The Eiger Biopharmaceuticals probability density function shows the probability of Eiger Biopharmaceutica stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Eiger Biopharmaceuticals has a beta of -1.5964 suggesting as returns on its benchmark rise, returns on holding Eiger Biopharmaceuticals are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Eiger Biopharmaceutica is expected to outperform its benchmark. Additionally, eiger Biopharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Eiger Biopharmaceutica to move above the current price in 90 days from now is about 97.0 (This Eiger Biopharmaceuticals probability density function shows the probability of Eiger Stock to fall within a particular range of prices over 90 days) .
Eiger Biopharmaceuticals Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Eiger Biopharmaceutica market risk premium is the additional return an investor will receive from holding Eiger Biopharmaceutica long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Eiger Biopharmaceutica. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Although Eiger Biopharmaceutica's alpha and beta are two of the key measurements used to evaluate Eiger Biopharmaceutica's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 6.83 | |||
| Standard Deviation | 13.26 | |||
| Variance | 175.79 | |||
| Risk Adjusted Performance | (0.02) |
Eiger Stock Against Markets
Picking the right benchmark for Eiger Biopharmaceutica stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Eiger Biopharmaceutica stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Eiger Biopharmaceutica is critical whether you are bullish or bearish towards Eiger Biopharmaceuticals at a given time. Please also check how Eiger Biopharmaceutica's historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eiger Biopharmaceutica without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Eiger Biopharmaceutica Corporate Directors
Eiger Biopharmaceutica corporate directors refer to members of an Eiger Biopharmaceutica board of directors. The board of directors generally takes responsibility for the Eiger Biopharmaceutica's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eiger Biopharmaceutica's board members must vote for the resolution. The Eiger Biopharmaceutica board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| David Apelian | Director | Profile | |
| Patrick Yang | Director | Profile | |
| Edgar Engleman | Director | Profile | |
| Charles Bramlage | Director | Profile |
How to buy Eiger Stock?
Before investing in Eiger Biopharmaceutica, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Eiger Biopharmaceutica. To buy Eiger Biopharmaceutica stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Eiger Biopharmaceutica. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Eiger Biopharmaceutica stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Eiger Biopharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Eiger Biopharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Eiger Biopharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments.
Already Invested in Eiger Biopharmaceuticals?
The danger of trading Eiger Biopharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eiger Biopharmaceutica is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eiger Biopharmaceutica. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eiger Biopharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eiger Biopharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Eiger Biopharmaceuticals information on this page should be used as a complementary analysis to other Eiger Biopharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Complementary Tools for Eiger Stock analysis
When running Eiger Biopharmaceutica's price analysis, check to measure Eiger Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eiger Biopharmaceutica is operating at the current time. Most of Eiger Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Eiger Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eiger Biopharmaceutica's price. Additionally, you may evaluate how the addition of Eiger Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Eiger Biopharmaceutica's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eiger Biopharmaceutica. If investors know Eiger will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eiger Biopharmaceutica listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Eiger Biopharmaceuticals is measured differently than its book value, which is the value of Eiger that is recorded on the company's balance sheet. Investors also form their own opinion of Eiger Biopharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Eiger Biopharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eiger Biopharmaceutica's market value can be influenced by many factors that don't directly affect Eiger Biopharmaceutica's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eiger Biopharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eiger Biopharmaceutica is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eiger Biopharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.